| Name | Title | Contact Details |
|---|
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
Omnibus Health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cigna-HealthSpring is a leading health service company committed to helping our nation`s Medicare and Medicaid beneficiaries live healthier, more active lives through personalized, affordable and easy-to-use health care solutions. Cigna-HealthSpring key products include Medicare Advantage, Medicare Prescription Drug Coverage, Medicaid and other health service products.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
SCP Health (SCP) is a clinical company. At our core we work to bring hospitals and healers together in the pursuit of clinical effectiveness. With a portfolio of over 8 million patients, 7500 providers, 30 states, and 400 healthcare facilities, SCP Health is a leader in clinical practice management spanning the entire continuum of care, including emergency medicine, hospital medicine, wellness, telemedicine, intensive care, and ambulatory care. Whether you`re a resident, nurse practitioner, physician assistant, physician, or medical director looking for a clinical career or a professional interested in opportunities at one of our corporate locations, we can find you a position that fits you professionally and personally.